C3.ai (NYSE: AI) trades at $10.18 as Wedbush Securities analyst Dan Ives maintains a Street-high price target of $15, implying roughly 47% upside from current levels.
Ives carries an Outperform rating on the enterprise AI software company, with his $15 target standing well above the broader Wall Street consensus average of just $8.82 across 14 covering analysts.
That consensus average sits below the current trading price, meaning most analysts effectively see further downside ahead for the struggling enterprise AI firm.
C3.ai sells the C3 Agentic AI Platform alongside industry-specific enterprise AI applications, competing for federal, defense, and industrial AI contracts across commercial and government markets.
Founder Thomas Siebel returned as CEO in June and personally purchased 6.17 million shares at $11.16, putting his own capital directly behind a turnaround strategy.
Fiscal 2026 revenue landed at $250.27 million, a 35.67% year-over-year decline, with Q4 alone posting revenue of $51.60 million, representing a 52.5% drop compared to the prior year period.
GAAP gross margin collapsed from 62% to 22% over the same period, while full-year free cash flow deteriorated sharply to negative $192.14 million.
Siebel described the recent sales performance as “unspeakably horrible,” adding that “sales just fell off the cliff” across the last five quarters of operation.
FY2027 revenue guidance of $210 million to $240 million implies further contraction before any meaningful recovery takes hold, with shares down 45.27% over the past year and 24.48% year to date.
Ives’ bull thesis rests on three pillars: C3.ai as an early enterprise pure-play for federal and commercial generative AI adoption, a shift toward consumption-based pricing, and a partner-led motion through Microsoft Azure, AWS, and Google Cloud.
Q3 FY2026 bookings from federal, defense, and aerospace segments grew 134% year over year, reaching 55% of total company bookings during that quarter.
The joint qualified pipeline with Microsoft grew 146% year over year, while the AWS joint pipeline expanded 172%, providing some credibility to the partner-driven revenue strategy.
Those figures align with a Pentagon budget request calling for $58.5 billion allocated to AI spending in FY2027, a tailwind that Ives believes will disproportionately benefit C3.ai’s government-facing business.
Broader analyst sentiment, however, remains deeply skeptical, with coverage showing zero Strong Buy ratings, one Buy, seven Holds, three Sells, and three Strong Sell recommendations across all 14 analysts.
Shares are down 24.48% year to date while the S&P 500 has gained 14.07%, representing a significant gap in relative performance that has rattled investor confidence.
Beta sits at 2.07, reflecting the stock’s high volatility profile, while Polymarket bettors put implied bankruptcy odds by year-end 2026 at 13.5%, down from levels seen a month earlier.
Securities class actions emerged following the Q1 FY2026 disclosure related to Siebel’s earlier health issues, adding legal uncertainty on top of the already challenging financial picture.
Compared to peers, Palantir (NASDAQ: PLTR) trades near $178.65 against a $191.68 consensus target with Q2 revenue climbing 92.8% to $1.94 billion, highlighting how far C3.ai has fallen behind on growth metrics.
SoundHound AI (NASDAQ: SOUN) trades near $7.98 with a $12.71 consensus target and Q2 revenue up 45% to $61.9 million, while BigBear.ai (NYSE: BBAI) trades near $3.26 against a $4 consensus estimate.
Ives’ $15 call represents a wider premium to consensus than any comparable peer, signaling the market currently views C3.ai as a pure execution story rather than a broader sector beneficiary, and Siebel’s response to skeptics has been characteristically blunt: “Game on.”
